Transthyretin Amyloidosis (ATTR) | Pfizer Medical Information

Congress Materials

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Back to Diseases Areas

Poster

Gonzalez-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia Pavia P, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

A Descriptive Analysis of Patients With ATTR Amyloidosis and a Mixed Phenotype From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation

Oral Presentation

Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy

View Presentation

Poster

Waddington Cruz M, Planté-Bordeneuve V, Inamo J, Kristen A, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ile107Val Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation

Poster

Diemberger I, Lino Cirami C, Luigetti M, Dispenzieri A, Grogan M, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ile68Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation

Poster

Luigetti M, DiPaolantonio A, Mazzeo A, Diemberger I, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Phe64Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation

Poster

Planté-Bordeneuve V, Dori A, Dispenzieri A, Grogan M, Adams D, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)